FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer

News
Article

The FDA has set a Prescription Drug User Fee Act date of June 29, 2024 for SH-105 as a treatment for patients with ovarian cancer or breast cancer.

Developers designed SH-105 as a ready-to-dilute formulation of a previously approved drug that has been used as a freeze-dried powder for the management of adenocarcinoma of the breast or ovary.

Developers designed SH-105 as a ready-to-dilute formulation of a previously approved drug that has been used as a freeze-dried powder for the management of adenocarcinoma of the breast or ovary.

A new drug application (NDA) for SH-105 as a treatment for those with breast cancer or ovarian cancer has been submitted to and accepted by the FDA, according to a press release from Shorla Oncology.1

The regulatory agency has set a Prescription Drug User Fee Act date of June 29, 2024 for their decision on SH-105 in the aforementioned patient populations.

Developers designed SH-105 as a ready-to-dilute formulation of a previously approved drug that has been used as a freeze-dried powder for the management of adenocarcinoma of the breast or ovary. The new formulation is believed to remove the need to reconstitute the powder based on its novel, differentiated liquid form, thereby improving efficiency and reducing the complexity associated with its preparation.

“This innovative drug will offer hospital pharmacists and patients access to a differentiated, ready to administer, injectable product with unique characteristics [which is] expected to facilitate rapid adoption once approved,” Orlaith Ryan, chief technical officer and co-founder at Shora Oncology, said in the press release.1

Manufacturers organized a successful pre–investigational new drug meeting with the FDA for SH-105 in June 2019.2 Developers stated that this “positive outcome strengthens [their] efforts to bring SH-105 to market benefiting [patients with] breast and ovarian cancer” and described the meeting as a “significant milestone on Shorla Oncology’s journey of bringing innovative oncology products to market.”2

According to the manufacturers, SH-105 is one of many oncology agents that comprise the company’s pipeline. Previously, the FDA approved nelarabine (Arranon) injection for treating those with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in March 2023.3 The nelarabine injection was designed to provide an alternative formulation of a product that may be in short supply.

“Successful treatment of children, adolescents and young adults with cancer, such as children with T-cell acute lymphoblastic leukemia, is dependent on stable access to critical chemotherapy agents,” Stephen P. Hunger, MD, chief of the Division of Oncology and director of the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia, said in a press release on the approval of the injection.3 “Drug shortages directly impact patient outcome. We are encouraged by the approval of nelarabine injection and the significant impact that we expect it will have on treatment access and patient care.”

Shora Oncology also announced a successful pre-investigational new drug application meeting with the FDA for SH-110, a novel agent for managing brain cancer, in October 2020.4 According to the developers, SH-110 may provide a significant benefit to those with brain cancer by diminishing the burden of treatment while offering an age-appropriate treatment.

“This is an important step in improving access to and administration of a drug that will help [patients with] breast and ovarian cancer. It also marks a significant milestone regarding Shorla’s efforts to bring innovative oncology products to market,” Sharon Cunningham, chief executive officer and co-founder at Shorla Oncology, said regarding the NDA submission for SH-105.1

References

  1. Shorla Oncology announces FDA Filing acceptance of new drug application for novel formulation to treat breast and ovarian cancer. News release. Shorla Oncology. January 9, 2024. Accessed January 11, 2024. https://shorturl.at/arv45
  2. SH-105 successful FDA pre-IND meeting. News release. Shorla Oncology. June 14, 2019. Accessed January 11, 2024. https://shorturl.at/bftOP
  3. Shorla Oncology announces U.S. FDA approval of nelarabine injection for the treatment of T-cell leukemia. News release. Shorla Oncology. March 7, 2023. Accessed January 11, 2024. https://shorturl.at/FU234
  4. SH-110 successful FDA pre-IND meeting. News release. Shorla Oncology. October 2, 2020. Accessed January 11, 2024. https://shorturl.at/guwIM
Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content
Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Camizestrant Significantly Improves PFS in HER2– Breast Cancer

Tim Cortese
November 12th 2024
Article

Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Early Palliative Care May Increase QOL in Ovarian Cancer Decedents Near EOL

Tim Cortese
November 4th 2024
Article

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Rolling NDA Completed for Avutometinib Combo in Ovarian Cancer Subtype

Russ Conroy
November 1st 2024
Article

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups

Russ Conroy
October 31st 2024
Article

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.